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OBJECTIVE—Coffee consumption has been inversely associ-
ated with type 2 diabetes risk, but its mechanisms are largely
unknown. We aimed to examine whether plasma levels of sex
hormones and sex hormone–binding globulin (SHBG) may ac-
count for the inverse association between coffee consumption
and type 2 diabetes risk.
RESEARCH DESIGN AND METHODS—We conducted a
case-control study nested in the prospective Women’s Health
Study (WHS). During a median follow-up of 10 years, 359
postmenopausal women with newly diagnosed type 2 diabetes
were matched with 359 control subjects by age, race, duration of
follow-up, and time of blood draw.
RESULTS—Caffeinated coffee was positively associated with
SHBG but not with sex hormones. Multivariable-adjusted geo-
metric mean levels of SHBG were 26.6 nmol/l among women
consuming 4 cups/day of caffeinated coffee and 23.0 nmol/l
among nondrinkers (P for trend  0.01). In contrast, neither
decaffeinated coffee nor tea was associated with SHBG or sex
hormones. The multivariable-adjusted odds ratio (OR) of type 2
diabetes for women consuming 4 cups/day of caffeinated coffee
compared with nondrinkers was 0.47 (95% CI 0.23–0.94; P for
trend  0.047). The association was largely attenuated after
further adjusting for SHBG (OR 0.71 [95% CI 0.31–1.61]; P for
trend  0.47). In addition, carriers of rs6259 minor allele and
noncarriers of rs6257 minor allele of SHBG gene consuming 2
cups/day of caffeinated coffee had lower risk of type 2 diabetes in
directions corresponding to their associated SHBG.
CONCLUSIONS—Our ﬁndings suggest that SHBG may account
for the inverse association between coffee consumption and type
2 diabetes risk among postmenopausal women. Diabetes 60:
269–275, 2011
P
revious prospective studies have documented an
inverse association between coffee consumption
and type 2 diabetes risk (1,2), especially in
women (2). Coffee intake may improve glucose
tolerance via activation of energy metabolism and en-
hancement of insulin sensitivity and -cell function (2,3)—
although much of the molecular mechanism remains
unknown. Previous cross-sectional studies have associ-
ated coffee intake with plasma levels of sex hormones or
sex hormone–binding globulin (SHBG) (4,5). In addition, a
large body of observational and experimental data has
implicated the important roles of sex hormones in the
development of type 2 diabetes (6–8). Notably, recent
experiments indicate that SHBG not only regulates the
biologically active fraction of sex hormones but may bind
to its own receptors at the plasma membranes of a variety
of cells, directly mediating intracellular signaling of sex
hormones (9). More recently, prospective studies of men
and women incorporating both genetic and phenotypic
assessment of SHBG revealed a strong inverse association
between SHBG levels and type 2 diabetes risk (10).
However, no studies have comprehensively evaluated the
interrelationships of coffee consumption in relation to sex
hormones and SHBG with respect to type 2 diabetes risk.
To examine whether and to what extent sex hormones or
SHBG may account for the potential protective effect of
coffee intake against type 2 diabetes, we analyzed data
from a prospective case-control study of women. In par-
ticular, we evaluated the associations of coffee consump-
tion with plasma levels of sex hormones and SHBG, as
well as the direct association between coffee consumption
and type 2 diabetes risk during a 10-year follow-up.
Moreover, we investigated whether the association of
coffee consumption with type 2 diabetes risk was attenu-
ated by further adjusting for plasma sex hormones or
SHBG. Finally, we examined whether coffee intake may
interact with speciﬁc SHBG genotypes in affecting diabe-
tes risk.
RESEARCH DESIGN AND METHODS
The Women’s Health Study (WHS) is a randomized, double-blind, placebo-
controlled trial originally designed to evaluate the balance of beneﬁts and
risks of low-dose aspirin and vitamin E in the primary prevention of
cardiovascular disease and cancer (11). Of the 39,876 participants aged 45
years and older, 98% of participants completed a 131-item semiquantitative
food frequency questionnaire (SFFQ). At baseline, participants were asked if
they were willing to provide blood samples by mail. Women who responded
afﬁrmatively and were eligible to be enrolled into the run-in phase were mailed
a blood collection kit. Of the 28,345 (71%) who provided baseline blood
samples, we restricted our study to 6,574 postmenopausal women who were
not using hormone replacement therapy (HRT) at the time of blood collection.
By February 2005, 366 of these initially healthy women reported developing
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diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 269incident type 2 diabetes. Control subjects were matched in 1:1 ratio to case
subjects by age (within 1 year), duration of follow-up (within 1 month), race,
and fasting status at time of blood draw (82% provided fasting blood samples,
deﬁned as 10 h since the last meal). Based on these eligibility criteria, 359
case subjects and 359 control subjects were included in our analyses. Written
informed consent was obtained from all participants. This study was approved
by the Institutional Review Boards of Brigham and Women’s Hospital, Harvard
Medical School, and the University of California, Los Angeles (UCLA).
Assessment of dietary intake. In the SFFQ, participants were asked how
often on average during the previous year they had consumed caffeinated and
decaffeinated coffee (“one cup”), tea (“one cup or glass”), different types of
caffeinated soft drinks (“one glass, bottle, or can”), and chocolate products
(e.g., “bar or packet”). Participants could choose from nine responses (never
or 1/month, 1–3/month, 1/week, 2–4/week, 5–6/week, 1/day, 2–3/day, 4–5/
day, and 6/day). Using U.S. Department of Agriculture food composition
data supplemented with other sources, we estimated that the caffeine content
was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per bottle or can
of cola beverage, and 7 mg per serving of chocolate candy (12). A validation
study from a similar cohort of women reported high correlations between
intake of coffee and other caffeinated beverages assessed with SFFQ and with
four 1-week diet records (coffee, r  0.78; tea, r  0.93; and caffeinated sodas,
r  0.85) (13).
Ascertainment of incident type 2 diabetes. Details regarding ascertain-
ment of incident type 2 diabetes in our cohorts have been reported previously
(14). After excluding those with diabetes at baseline, all participants were
asked annually whether and when they had a diagnosis of diabetes since
baseline. Using the diagnostic criteria of the American Diabetes Association
(15), all self-reported cases of type 2 diabetes were conﬁrmed by a supple-
mental questionnaire. Self-reported diabetes in the WHS was validated against
physician-led telephone interviews, supplementary questionnaires, and medi-
cal record reviews, all yielding positive predictive values 91% (16).
Laboratory procedures. A mailed blood collection kit contained instruc-
tions, three 10-ml EDTA vacutainer tubes, three 4.5-ml sodium citrate tubes,
supplies needed to draw a sample of blood, a completed overnight courier air
bill, and a gel-ﬁlled freezer pack. The gel-ﬁlled freezer pack was frozen
overnight to serve as a coolant for mailing. Women were asked to have a
morning fasting blood sample drawn into two EDTA and two citrate tubes,
and to return the completed blood kit via overnight courier. All samples
arrived in our laboratory within 24–30 h of venipuncture. Upon receipt,
samples were kept chilled until processed. After centrifugation for 20 min
(2,500 rpm, 4°C) each sample was pipetted into 2 ml Nunc vials. Samples were
stored in liquid nitrogen tanks until the time of laboratory analyses. Labora-
tory personnel were blinded to case-control status, and matched case-control
pairs were handled identically and assayed in random order in the same
analytical run. Plasma concentrations of sex hormones and SHBG were
measured using chemiluminescent immunoassays (Elecsys autoanalyzer 2010;
Roche Diagnostics, Indianapolis, IN), which have been validated for measur-
ing plasma sex hormones and SHBG (17–19). For the hormone levels in this
study, the coefﬁcients of variation from blinded quality control samples were
5.2% for estradiol, 7.4% for testosterone, 2.8% for dehydroepiandrosterone
sulfate (DHEAS), and 2.8% for SHBG. Detailed methods for single nucleotide
polymorphism (SNP) selection and genotyping of SHBG SNPs were described
previously (10). Two informative SNPs associated with plasma SHBG levels
were included in our study: rs6259 in exon 8, encoding an amino acid
substitution of asparagine for aspartic acid, which may lead to reduced
clearance rate of SHBG, and rs6257 in intron 1.
Statistical analysis. Following conventional practice in previous studies, we
categorized caffeinated coffee, decaffeinated coffee, and tea consumption by
aggregating nine possible responses for caffeinated coffee, decaffeinated
coffee, and tea from SFFQ into four categories (0 cups/day, 1 cups/day, 2–3
cups/day, and 4 cups/day). We also categorized caffeine consumption into
four categories (50, 51–250, 251–500, and 500 mg/day).
Baseline characteristics were compared between case patients and control
subjects using the paired t test for continuous variables and McNemar test for
categorical variables. To assess the association of caffeine-related beverage
consumption (caffeinated coffee, decaffeinated coffee, tea, and caffeine) with
sex hormones (estradiol, testosterone, and DHEAS) and SHBG, we calculated
the geometric means of sex hormones and SHBG plasma levels according to
the four categories of caffeine-related beverage consumption. We used multi-
ple linear regression models to adjust for matching factors (age, race, duration
of follow-up, and time of blood draw), smoking status (never, past, and
current smokers), physical activity (rarely/never, 1, 1–3, and 4 times/
week), alcohol use (rarely/never, 1–3 drinks/month, 1–6 drinks/week, and 1
drinks/day), total calories (1,500, 1,501–2,000, 2,001–2,500, and 2,500
kcal/day), and BMI (continuous). To test for a linear trend across increasing
categories of caffeine-related beverage consumption, we computed the me-
TABLE 1
Baseline characteristics between participants with incident cases of type 2 diabetes and control participants among 718 women
Case
subjects
Control
subjects P*
n 359 359
Age (years) 60.3  6.1 60.3  6.1
Caucasian (%) 93.5 93.5
BMI (kg/m
2) 30.9  6.1 26.0  5.0 0.001
Alcohol (g/day) 2.62  7.4 4.19  8.3 0.008
Current smoking (%) 14.5 13.7 0.74
Physical activity once/week (%) 30.7 38.7 0.02
Family history of diabetes (%) 48.5 24.0 0.001
Past postmenopausal hormone use (%) 34.0 29.3 0.17
Ever oral contraceptive use (%) 50.4 48.0 0.57
Age at menopause (years) 48.0  6.2 48.0  5.8 0.79
Years since menopause 12.2  8.2 12.2  8.0 0.77
Age at menarche 12 (%) 25.4 21.7 0.23
Age at ﬁrst pregnancy of 6 months, 25 (%) 63.4 57.2 0.37
Pregnancies 5 (%) 18.7 19.9 0.69
Currently married (%) 65.7 68.2 0.28
Caffeine-related beverages
Caffeinated coffee, 4 cups/day (%) 13.8 20.9 0.01
Decaffeinated coffee, 4 cups/day (%) 2.3 4.3 0.20
Tea, 4 cups/day (%) 5.2 2.9 0.13
Caffeine, 500 mg/day (%) 14.3 21.1 0.02
Sex hormones
SHBG (nmol/l) 22.3  13.8 36.9  17.4 0.001
Estradiol (pg/ml) 24.6  15.9 20.5  11.3 0.001
Testosterone (ng/dl) 29.8  19.1 28.9  19.1 0.49
DHEAS (g/dl) 91.0  61.3 92.6  53.7 0.67
Data are means  SD. *Baseline characteristics were compared between case patients and control subjects using the paired t test for
continuous variables and the McNemar test for categorical variables.
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multiple linear regression models.
To assess the relations of caffeine-related beverage consumption with type
2 diabetes risk, we used conditional logistic regression models to adjust for
matched pairs (match-adjusted model). We further adjusted for smoking
status (never, past, and current smokers), physical activity (rarely/never, 1,
1–3, and 4 times/week), family history of diabetes (yes or no), alcohol use
(rarely/never, 1–3 drinks/month, 1–6 drinks/week, and 1 drinks/day), total
calories (1,500, 1,501–2,000, 2,001–2,500, and 2,500 kcal/day), and BMI
(continuous) (categorical model). To test for a linear trend across increasing
categories of caffeine-related beverage consumption, we computed the me-
dian value for each category and included this as a continuous variable in the
conditional logistic regression models. Because caffeine and caffeinated coffee
consumption were associated with plasma SHBG levels but not with sex
hormones, in subsequent analyses, we further included plasma SHBG levels
(20.0, 20.1–25.0, 25.1–30.0, and 30.0 nmol/l) in the models (categorical
model  SHBG).
To further provide a visual representation of the dose-response curve, we
ﬁtted quadratic spline models by including transformed variables of caffeine-
related beverage consumption to multiple regression models using a single
knot at the middle category boundary used in each categorical model (20).
Finally, we examined potential effect modiﬁcation by two informative SHBG
SNPs, rs6259 and rs6257, using the dominant genetic model. We calculated
adjusted plasma SHBG levels and odds ratios (ORs) of type 2 diabetes for
combinations of SHBG genotypes and caffeinated coffee intake levels (2
cups/day vs. 2 cups/day). Wald tests were used to test for statistical
interaction by entering product terms to the regression models. We performed
the 
2 test to evaluate Hardy-Weinberg equilibrium for rs6259 and rs6257
among the control subjects. All statistical analyses were conducted using SAS
(version 9.2; SAS institute, Cary, NC).
TABLE 2
Geometric mean levels of plasma SHBG (nmol/l) according to caffeinated coffee, decaffeinated coffee, tea, and caffeine consumption
Categories of intake *P for
trend 0 cups/day 1 cups/day 2–3 cups/day 4 cups/day
Caffeinated coffee, median (n) 0 (185) 1.0 (187) 2.5 (212) 4.5 (122)
Match-adjusted model§ 23.1 (16.1–33.1) 22.7 (15.8–32.7) 24.7 (17.2–35.5) 27.6 (19.1–39.9) 0.002
Categorical model† 23.0 (16.5–32.0) 22.8 (16.3–31.8) 23.6 (16.9–33.0) 26.6 (18.9–37.4) 0.01
Spline model‡ 22.9 (16.5–31.9) 22.7 (16.2–31.8) 24.1 (17.2–33.6) 26.0 (18.5–36.5)
Decaffeinated coffee, median (n) 0 (401) 0.4 (188) 2.5 (84) 4.5 (23)
Match-adjusted model§ 24.5 (17.1–35.2) 24.3 (16.8–35.4) 25.2 (17.1–37.3) 26.7 (17.4–40.9) 0.44
Categorical model† 23.7 (17.0–33.1) 22.3 (15.8–31.3) 23.2 (16.2–33.3) 22.9 (15.5–33.9) 0.75
Spline model‡ 23.6 (16.9–32.9) 23.5 (16.8–33.0) 23.6 (16.5–33.6) 23.5 (16.2–34.3)
Tea, median (n) 0 (242) 0.4 (351) 2.5 (76) 4.5 (28)
Match-adjusted model§ 25.6 (17.9–36.7) 23.6 (16.4–33.8) 24.6 (16.9–35.8) 21.6 (14.3–32.5) 0.27
Categorical model† 24.5 (17.6–34.1) 23.3 (16.7–32.6) 23.3 (16.5–32.8) 21.4 (14.7–31.3) 0.24
Spline model‡ 24.4 (17.5–33.9) 23.7 (17.0–33.1) 22.5 (16.1–31.5) 22.7 (15.9–32.3)
Caffeine category (mg/day) 50 51–250 251–500 500
Caffeine intake (mg/day), median (n) 13 (131) 140 (209) 366 (230) 656 (123)
Match-adjusted model§ 22.9 (15.8–33.0) 22.5 (15.6–32.5) 23.6 (16.4–34.0) 26.9 (18.5–39.0) 0.008
Categorical model† 22.9 (16.5–32.0) 23.2 (16.7–32.3) 23.0 (16.5–32.1) 26.6 (19.0–37.4) 0.02
Spline model‡ 23.0 (16.5–32.1) 23.0 (16.6–32.0) 23.7 (17.0–33.0) 25.6 (18.3–35.8)
Data are geometric means (95% CI) unless otherwise indicated. *P values for trend are based on median values in categories of the
participants. §Match-adjusted model: adjusted for age, race, duration of follow-up, and time of blood draw. †Categorical model: adjusted for
matching factors, smoking status, physical activity, alcohol use, total calories, and BMI. ‡Spline model: estimates at category medians from
quadratic spline regression models with one knot at the middle category boundaries, adjusted for covariates used in categorical model.
TABLE 3
Geometric mean levels of total estradiol, total testosterone, and DHEAS according to caffeinated coffee, decaffeinated coffee, tea, and
caffeine consumption
0 cups/day 1 cups/day 2–3 cups/day 4 cups/day
P for
trend
Caffeinated coffee, median (n) 0 (185) 1.0 (187) 2.5 (212) 4.5 (122)
Total estradiol (pg/ml) 23.6 (17.9–31.1) 21.2 (16.1–28.1) 23.9 (18.0–31.6) 22.0 (16.5–29.2) 0.76
Total testosterone (ng/dl) 20.7 (13.4–32.0) 21.5 (13.8–33.3) 22.8 (14.6–35.4) 22.3 (14.3–35.0) 0.23
DHEAS (g/dl) 87.8 (57.6–133.7) 89.0 (58.2–136.1) 94.4 (61.6–144.6) 93.3 (60.4–144.0) 0.28
Decaffeinated coffee, median (n) 0 (401) 0.4 (188) 2.5 (84) 4.5 (23)
Total estradiol (pg/ml) 23.0 (17.4–30.5) 21.6 (16.2–28.8) 22.7 (16.8–30.8) 21.8 (15.7–30.3) 0.67
Total testosterone (ng/dl) 21.0 (13.6–32.4) 18.7 (11.9–29.2) 19.7 (12.3–31.6) 19.9 (11.9–33.3) 0.55
DHEAS (g/dl) 86.3 (56.5–131.8) 83.1 (53.8–128.5) 84.5 (53.5–133.6) 88.5 (53.7–145.6) 0.99
Tea, median (n) 0 (242) 0.4 (351) 2.5 (76) 4.5 (28)
Total estradiol (pg/ml) 22.9 (17.3–30.2) 23.5 (17.8–31.1) 24.6 (18.5–32.7) 22.4 (16.3–30.8) 0.60
Total testosterone (ng/dl) 21.7 (14.1–33.6) 23.0 (14.8–35.6)` 21.9 (14.0–34.3) 19.7 (11.9–32.4) 0.49
DHEAS (g/dl) 87.8 (57.7–133.5) 94.9 (62.2–144.8) 88.2 (57.2–136.1) 78.1 (48.3–126.2) 0.36
Caffeine category (mg/day) 50 50–249 250–499 500
Caffeine intake, median (mg/day) (n) 13 (131) 140 (209) 366 (230) 656 (123)
Total estradiol (pg/ml) 23.0 (17.4–30.4) 22.4 (16.9–29.5) 24.2 (18.3–32.0) 22.4 (16.9–29.8) 0.79
Total testosterone (ng/dl) 19.4 (12.5–30.0) 21.9 (14.2–33.8) 22.1 (14.2–34.2) 22.1 (14.2–34.5) 0.21
DHEAS (g/dl) 84.2 (55.1–128.7) 90.2 (59.1–137.6) 92.3 (60.3–141.3) 90.5 (58.7–139.5) 0.42
Data are geometric means (95% CI). *P for trend are based on median values in categories of the participants. All models were adjusted for
matching factors (age, race, duration of follow-up, and time of blood draw), smoking status, physical activity, alcohol use, total calories, and
BMI.
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Compared with control participants, diabetic subjects had
a greater proportion of traditional risk factors at baseline
(Table 1). Diabetic subjects had higher levels of plasma
total estradiol and lower levels of plasma SHBG, but
plasma total testosterone and DHEAS appeared to be
similar between case and control subjects.
Caffeinated coffee and caffeine intakes were positively
associated with plasma SHBG levels but not with sex
hormones (Table 2 and Table 3). For caffeinated coffee,
the multivariate-adjusted geometric mean levels of plasma
SHBG were 26.6 nmol/l (95% CI 18.9–37.4) in women
consuming 4 cups/day and 23.0 nmol/l (16.5–32.0) in
nondrinkers (P for trend  0.01). For caffeine, the multi-
variate-adjusted geometric mean levels of plasma SHBG
were 26.6 nmol/l (19.0–37.4) in women consuming 500
mg/day and 22.9 nmol/l (16.5–32.0) in women consuming
50 mg/day (P for trend  0.02) (Table 2). We found
similar results using quadratic spline models that imposed
smooth dose-response relations (Table 2 and Fig. 1A). The
spline plots indicated that heavy drinkers of caffeinated
coffee (2 cups/day) were associated with higher levels of
plasma SHBG (Fig. 1A). In contrast, decaffeinated coffee
and tea intakes were not associated with plasma SHBG
levels and sex hormone levels (Table 3).
Caffeinated coffee and caffeine intakes were also in-
versely associated with risk of type 2 diabetes (Table 4).
The multivariate-adjusted ORs of type 2 diabetes were 0.47
(95% CI 0.23 – 0.94; P for trend  0.047) for 4 cups/day of
caffeinated coffee compared with nondrinkers and 0.56
(0.27–1.15; P for trend  0.18) for 500 mg/day compared
with 50 mg/day of caffeine. Little or no association of
decaffeinated coffee and tea consumption with type 2
diabetes was observed. After further adjusting for plasma
SHBG levels, the inverse associations of caffeinated coffee
and caffeine with type 2 diabetes risk were attenuated
(categorical model  SHBG). Compared with nondrinkers,
the ORs for 4 cups/day of caffeinated coffee changed
from 0.47 to 0.71 (0.31–1.61; P for trend  0.47). Similarly,
compared with 50 mg/day of caffeine, the ORs for 500
mg/day were changed from 0.56 to 0.89 (0.38–2.10; P for
trend  0.91). In contrast, further adjustment for plasma
sex hormones instead of SHBG did not change the asso-
ciation. Similar results were shown in our ﬁtted spline
logistic regression models (Table 4, Spline model). In the
spline plots, before adjusting for plasma SHBG, an inverse
trend between caffeinated coffee and risk of type 2 diabe-
tes was observed above 2 cups/day of caffeinated coffee
(Fig. 1B). This trend disappeared after further adjusting
for plasma SHBG (Fig. 1C).
Finally, we estimated the multivariable-adjusted geo-
metric mean levels of plasma SHBG and multivariable-
adjusted ORs of type 2 diabetes for combinations of SHBG
genotypes and caffeinated coffee intake levels (2 cups/
day vs. 2 cups/day) (Table 5). We detected no departure
from Hardy-Weinberg equilibrium for rs6259 and rs6257
SNPs among the control subjects (P  0.24 and P  0.06,
respectively). Carriers of the rs6259 minor allele and
noncarriers of the rs6257 minor allele who reported high
intake of caffeinated coffee had a lower risk of type 2
diabetes in directions corresponding to their associated
plasma SHBG levels. Compared with low-drinkers (2
cups/day) without the rs6259 minor allele, high-drinkers
(2 cups/day) with the minor allele had 20% higher plasma
SHBG levels (27.8 vs. 23.2 nmol/l) and were associated
with lower risk of type 2 diabetes (OR 0.54 [95% CI
0.26–1.11]). Similarly, compared with low-drinkers (2
cups/day) with the rs6257 minor allele, high-drinkers (2
cups/day) without the minor allele had 24% higher plasma
SHBG levels (25.2 vs. 20.3 nmol/l) and were associated
with lower risk of type 2 diabetes (0.38 [0.18–0.83]).
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FIG. 1. Estimated plasma SHBG and risk of type 2 diabetes in women
according to caffeinated coffee consumption. A: The geometric mean
SHBG levels adjusted for matching factors, smoking status, physical
activity, family history of diabetes, alcohol use, total calories, and BMI
from quadratic spline model (solid curve) with pointwise 95% conﬁ-
dence limits (dashed curves). B: The OR of type 2 diabetes from
quadratic conditional logistic spline model adjusted for matching
factors, smoking status, physical activity, family history of diabetes,
alcohol use, total calories, and BMI (solid curve) with pointwise 95%
conﬁdence limits (dashed curves). C: The multivariate-adjusted OR of
type 2 diabetes from quadratic conditional logistic spline model with
further adjustment for plasma SHBG.
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In this prospective study of postmenopausal women, caf-
feinated coffee and caffeine intakes were positively asso-
ciated with plasma SHBG levels. Also, we observed an
inverse association between intake of caffeinated coffee
and caffeine and risk of type 2 diabetes. The associations
were largely attenuated after adjustment for SHBG levels.
Finally, carriers of the rs6259 minor allele and noncarriers
of the rs6257 minor allele who reported high intake of
caffeinated coffee had a lower risk of type 2 diabetes in
directions corresponding to their associated plasma SHBG
levels. These ﬁndings suggest that SHBG may account for
TABLE 4
ORs for type 2 diabetes according to caffeinated coffee, decaffeinated coffee, tea, and caffeine consumption
0
cups/day 1 cups/day 2–3 cups/day 4 cups/day
P for
trend*
Caffeinated coffee (case subjects/control subjects) 99/86 103/84 105/107 49/73
Median (cups/day) 0 1.0 2.5 4.5
Match-adjusted model† 1.00 1.04 (0.68–1.60) 0.82 (0.55–1.23) 0.55 (0.34–0.90) 0.008
Categorical model‡ 1.00 0.95 (0.52–1.74) 0.94 (0.53–1.67) 0.47 (0.23–0.94) 0.047
Categorical model  SHBG§ 1.00 0.92 (0.46–1.84) 0.96 (0.48–1.94) 0.71 (0.31–1.61) 0.47
Spline model 1.00 1.11 (0.63–1.97) 0.92 (0.55–1.54) 0.61 (0.34–1.11)
Spline model  SHBG¶ 1.00 0.87 (0.45–1.68) 0.86 (0.47–1.58) 0.80 (0.39–1.65)
Decaffeinated coffee (case subjects/control subjects) 211/190 94/94 37/47 8/15
Median (cups/day) 0 0.4 2.5 4.5
Match-adjusted model† 1.00 0.87 (0.60–1.26) 0.63 (0.38–1.03) 0.49 (0.20–1.20) 0.03
Categorical model‡ 1.00 1.16 (0.70–1.95) 0.77 (0.38–1.55) 0.72 (0.19–2.69) 0.39
Categorical model  SHBG§ 1.00 1.03 (0.56–1.90) 1.11 (0.46–2.71) 1.33 (0.27–6.49) 0.71
Spline model 1.00 1.30 (0.90–1.88) 0.61 (0.33–1.14) 0.47 (0.17–1.29)
Spline model  SHBG¶ 1.00 1.31 (0.84–2.03) 0.91 (0.42–2.00) 0.92 (0.26–3.27)
Tea (case subjects/control subjects) 114/128 180/171 37/39 18/10
Median (cups/day) 0 0.4 2.5 4.5
Match-adjusted model† 1.00 1.21 (0.87–1.69) 1.06 (0.64–1.74) 2.03 (0.91–4.54) 0.23
Categorical model‡ 1.00 1.12 (0.70–1.77) 1.22 (0.59–2.50) 1.53 (0.43–5.47) 0.46
Categorical model  SHBG§ 1.00 0.97 (0.55–1.72) 1.14 (0.48–2.72) 1.74 (0.44–6.93) 0.42
Spline model 1.00 1.39 (0.99–1.93) 1.52 (0.83–2.77) 1.32 (0.51–3.38)
Spline model  SHBG¶ 1.00 1.37 (0.93–2.03) 1.37 (0.67–2.78) 1.57 (0.54–4.58)
Caffeine category (mg/day) 50 51–250 251–500 500
Caffeine intake (mg/day), median 13 140 366 656
(case subjects/control subjects) 67/64 109/100 118/112 49/74
Match-adjusted model† 1.00 1.01 (0.65–1.56) 0.99 (0.63–1.54) 0.62 (0.37–1.04) 0.06
Categorical model‡ 1.00 1.00 (0.56–1.82) 1.26 (0.68–2.32) 0.56 (0.27–1.15) 0.18
Categorical model  SHBG§ 1.00 0.94 (0.47–1.88) 1.44 (0.68–3.04) 0.89 (0.38–2.10) 0.91
Spline model 1.00 1.56 (0.80–3.04) 1.56 (0.81–3.01) 0.92 (0.48–1.76)
Spline model  SHBG¶ 1.00 1.53 (0.71–3.30) 1.70 (0.79–3.62) 1.32 (0.61–2.82)
Data are OR (95% CI) unless otherwise indicated. *P for trend values are based on median levels in categories. †Match-adjusted model:
stratiﬁed on matched pairs using conditional logistic regression models. ‡Categorical model: further adjusted for smoking status, physical
activity, family history of diabetes, alcohol use, total calories, and BMI. §Categorical model  SHBG: further adjusted for plasma SHBG.
Spline model: ORs comparing odds at category medians from quadratic logistic spline models with one knot at the middle category
boundaries adjusted for covariates used in categorical model. ¶Spline model  plasma SHBG: further adjusted for plasma SHBG.
TABLE 5
Caffeinated coffee consumption in relation to plasma SHBG levels and type 2 diabetes stratiﬁed by SHBG SNPs
SHBG genotype
rs6259 rs6257
GG (wild type) AG or AA (variant) CT or CC (variant) TT (wild type)
Plasma SHBG levels (nmol/l)* nn nn
Caffeinated coffee intake
Low (2 cups per day) 277 23.2 (16.6–32.5) 70 23.3 (16.4–32.9) 69 20.3 (14.2–29.0) 285 23.2 (16.6–32.4)
High (2 cups per day) 246 24.4 (17.4–34.3) 76 27.8 (19.4–39.7) 72 21.6 (15.2–30.8) 244 25.2 (17.9–35.4)
P for interaction† 0.18 0.84
ORs‡
(Case subjects/control
subjects)
(Case subjects/control
subjects)
(Case subjects/control
subjects)
(Case subjects/control
subjects)
Caffeinated coffee intake
Low (2 cups/day) 152/125 1.00 (reference) 40/30 0.90 (0.40–2.00) 42/27 1.00 (reference) 149/136 0.41 (0.19–0.88)
High (2 cups/day) 122/124 0.70 (0.42–1.16) 26/50 0.54 (0.26–1.11) 34/38 0.40 (0.16–1.02) 109/135 0.38 (0.18–0.83)
P for interaction† 0.79 0.13
Data are OR (95% CI) and n. *The multivariate-adjusted geometric mean SHBG levels with 95% CIs for combinations of SHBG genotypes and
caffeinated coffee intake levels (2 vs. 2 cups/day) adjusted for matching factors, smoking status, physical activity, family history of
diabetes, alcohol use, total calories, and BMI. †Wald tests were used to test for statistical interaction by entering product terms into the
regression models. ‡The multivariate-adjusted ORs and 95% CIs of type 2 diabetes risk for combinations of SHBG genotypes and caffeinated
coffee intake levels (2 vs. 2 cups/day) adjusted for matching factors, smoking status, physical activity, family history of diabetes, alcohol
use, total calories, and BMI.
A. GOTO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 273the inverse association between caffeinated coffee and
type 2 diabetes risk.
The inverse associations of caffeinated coffee and caf-
feine intake with type 2 diabetes risk observed in our study
are consistent with ﬁndings from previous studies (1,2).
Several possible explanations have been put forth to
explain the protective effect of coffee consumption on type
2 diabetes risk, including effects on insulin sensitivity and
-cell function by varying coffee components such as
magnesium, potassium, chlorogenic acid, and caffeine (2).
To date, however, little is known about the underlying
mechanisms. Evidence from a systematic review suggests
the sex differences in the inverse association between
coffee and type 2 diabetes risk (2). Moreover, both obser-
vational and experimental data indicate the important
roles of sex hormones in the development of type 2
diabetes (6–8). SHBG is synthesized primarily in the liver
and binds androgens with high afﬁnity and estrogens with
low afﬁnity, thereby regulating the biologically active
fraction of sex hormones (21). Recently, it has been shown
that the plasma membranes of a variety of cells are able to
bind SHBG speciﬁcally and with high afﬁnity, and SHBG
mediates sex hormones signaling at the cell membrane
through the SHBG receptors (9). This discovery of the
function of SHBG as a mediator of a steroid-signaling
system has drawn much interest to the biological effects of
SHBG. We ﬁrst reported that lower levels of SHBG may be
causally associated with type 2 diabetes risk using Men-
delian randomization analyses (10), ﬁndings of which have
been replicated by a large consortium of case-control
studies (22). Taken together, we hypothesized that caffein-
ated coffee consumption may lower the risk of type 2
diabetes possibly by altering SHBG metabolism.
We found that caffeine and caffeinated coffee intakes
were positively associated with plasma SHBG levels,
which is consistent with earlier studies (4,5,23–25). Little
or no association between decaffeinated coffee and plasma
SHBG levels suggest that caffeine may be a key component
of coffee responsible for determining plasma SHBG levels.
Moreover, our ﬁndings of little or no relations between
caffeine-related beverage consumption and sex hormones
suggest that caffeine may increase the level of plasma
SHBG without directly altering sex hormones levels. Caf-
feine and other major components of coffee (cafestol and
kahweol) alter expression and activity of liver enzymes
(26–29). Because SHBG is synthesized and metabolized
primarily in the liver (21), coffee intake may affect SHBG
metabolism in the liver and inﬂuence the plasma levels of
SHBG (5).
Coffee may increase plasma SHBG levels, resulting not
only in affecting the biological actions of sex hormones by
binding to circulating androgens and estrogens but also in
exerting direct metabolic effects (9). Our ﬁndings thus
provide a new explanation for the potential protective
effect of coffee consumption on the type 2 diabetes risk.
Notably, we found that carriers of the rs6259 minor allele
and noncarriers of the rs6257 minor allele who reported
high intake of caffeinated coffee had a lower risk of type 2
diabetes in directions corresponding to their associated
plasma SHBG levels. These ﬁndings may further support
the notion that SHBG may account for the potential
protective effect of caffeinated coffee on type 2 diabetes. In
contrast, the role of speciﬁc sex-steroids in relation to the
coffee-diabetes relation remains to be determined.
The strengths of our study include its prospective study
design with 10-year follow-up with comprehensive assess-
ment of baseline variables, blood samples, and SHBG
genotypes. Nevertheless, our study has several limitations.
First, cross-sectional analyses of coffee consumption and
plasma SHBG may be a concern, although it is not likely
that endogenous sex hormones or SHBG would inﬂuence
the consumption. Second, we cannot exclude the possibil-
ities of residual confounding from unmeasured or incom-
pletely measured covariates even though we have adjusted
for many major risk factors for type 2 diabetes. Third,
misclassiﬁcations of dietary intakes and biomarker mea-
sures are inevitable. For example, there may be measure-
ment errors of plasma sex hormones and SHBG because of
the limitations of stored samples. However, because case
subjects were identiﬁed prospectively and case-control
pairs were matched and handled in an identical fashion in
the same analytical run, any potential misclassiﬁcations
should affect case and control subjects equally. Therefore,
such misclassiﬁcations were likely to be nondifferential,
which would lead to an underestimation of the associa-
tions. Fourth, there is a concern about the possibility of
residual confounding from unmeasured time-dependent
confounders when a standard method is performed to
adjust for both an exposure and a measured intermediate
variable. However, we consider it is less likely that such
residual confounding would substantially explain our ﬁnd-
ings, because our observed associations appear to be
consistent with the observed genetically determined
SHBG levels when stratifying by SHBG genotypes. Finally,
our study only included postmenopausal women, which
may limit the generalizability of our ﬁndings to premeno-
pausal women or men.
In conclusion, our results suggest that SHBG levels may
account for the potential protective effect of habitual
coffee consumption against type 2 diabetes risk among
postmenopausal women. A better understanding of the
underlying mechanisms requires further investigation in
both observational and experimental settings.
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